PIK3CA mutations and PTEN loss in salivary duct carcinomas

American Journal of Surgical Pathology

Volumn 37, Issue 8, 2013, Pages 1201-1207

  Griffith, Christopher C ^a   Seethala, Raja R ^a   Luvison, Alyssa ^a   Miller, Megan ^a   Chiosea, Simion I ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

PI3K; PIK3CA; PTEN; salivary duct carcinoma

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

AGED; ARTICLE; CARCINOMA; CHROMOSOME 10; DISEASE FREE SURVIVAL; ENZYMOLOGY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC PREDISPOSITION; GENETICS; HEMIZYGOTE; HOMOZYGOTE; HUMAN; KAPLAN MEIER METHOD; MALE; MONOSOMY; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SALIVARY GLAND DUCT; SALIVARY GLAND TUMOR; TIME;

AGED; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 10; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; HEMIZYGOTE; HOMOZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MONOSOMY; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PTEN PHOSPHOHYDROLASE; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; TIME FACTORS;

EID: 84880536377     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182880d5a     Document Type: Article

References (36)

1. Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192: 100-105
2. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72:1503-1512
3. Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: A report of 50 cases. Cancer. 2005;103:2526-2533
4. Guzzo M, Di Palma S, Grandi C, et al. Salivary duct carcinoma: Clinical characteristics and treatment strategies. Head Neck. 1997;19:126-133
5. Williams MD, Roberts D, Blumenschein GR Jr., et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: Biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31: 1645-1652
6. Hosal AS, Fan C, Barnes L, et al. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 2003;129:720-725
7. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038
8. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: An immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586
9. Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009;123:250-252
10. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review. Med Oncol. 2012;29:704-706
11. Jaspers HC, Verbist BM, Schoffelen R, et al. Androgen receptorpositive salivary duct carcinoma: A disease entity with promising new treatment options. J Clin Oncol. 2011;29:e473-e476
12. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554
13. Mason VL. American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: Part 2. IDrugs. 2010;13:360-362
14. Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res. 2013;73:276-284
15. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29:4688-4695
16. Nakabayashi M, Werner L, Courtney KD, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110:1729-1735
17. Liedtke C, Cardone L, Tordai A, et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res. 2008;10:R27
18. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777-782
19. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005;7:R609-R616
20. Kadota M, Sato M, Duncan B, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009;69: 7357-7365
21. Wu X, Senechal K, Neshat MS, et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1998;95:15587-15591
22. Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106:719-726
23. Edge DRB SB, Compton CC, Fritz AG, et al. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer; 2009
24. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801-806
25. Di Palma S, Simpson RH, Marchio C, et al. Salivary duct carcinomas can be classified into luminal androgen receptorpositive, HER2 and basal-like phenotypes. Histopathology. 2012. [Epub ahead of print].
26. Prince ME, Ubell ML, Castro J, et al. Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head Neck. 2007;29:465-471
27. Hurst CD, Zuiverloon TC, Hafner C, et al. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes. 2009; 2:66
28. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105:418-424
29. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009;218: 505-513
30. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011;128:447-456
31. Woenckhaus J, Steger K, Werner E, et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol. 2002;198:335-342
32. Lewis JE, McKinney BC, Weiland LH, et al. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223-230
33. Wirth LJ, Nardi V, Juric D, et al. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. ASCO Meeting Abstracts. 2011;29:5579
34. Piha-Paul SA, Cohen PR, Kurzrock R. Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011;29:e727-e730
35. Suzuki S, Dobashi Y, Minato H, et al. EGFR and HER2- Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch. 2012;461: 271-282
36. Nagao T, Gaffey TA, Serizawa H, et al. Sarcomatoid variant of salivary duct carcinoma: Clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol. 2004;122:222-231